SARS-CoV-2 Infection in Multiple Sclerosis
Arrambide, Georgina (Hospital Universitari Vall d'Hebron)
Llaneza-González, Miguel Ángel (Hospital Universitari Vall d'Hebron)
Costa-Frossard, Lucienne (Hospital Universitari Vall d'Hebron)
Meca-Lallana, Virginia (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Díaz, Eva Fernández (Hospital Universitari Vall d'Hebron)
Moreno-Torres, Irene (Hospital Universitari Vall d'Hebron)
García-Domínguez, Jose Manuel (Hospital Universitari Vall d'Hebron)
Ortega-Suero, Gloria (Hospital Universitari Vall d'Hebron)
Ayuso-Peralta, Lucía (Hospital Universitari Vall d'Hebron)
Gómez-Moreno, Mayra (Hospital Universitari Vall d'Hebron)
Sotoca Fernández, Javier (Hospital Universitari Vall d'Hebron)
Caminero, Ana B (Hospital Universitari Vall d'Hebron)
Rodríguez de Antonio, Luis A. (Hospital Universitari Vall d'Hebron)
Corujo-Suárez, Marcial (Hospital Universitari Vall d'Hebron)
Otano-Martínez, María A. (Hospital Universitari Vall d'Hebron)
Pérez-Miralles, Francisco Carlos (Hospital Universitari Vall d'Hebron)
Reyes-Garrido, Virginia (Hospital Universitari Vall d'Hebron)
Ayuso-Blanco, Teresa (Hospital Universitari Vall d'Hebron)
Balseiro-Gómez, José (Hospital Universitari Vall d'Hebron)
Muñoz-Pasadas, Mercedes (Hospital Universitari Vall d'Hebron)
Pérez-Molina, Inmaculada (Hospital Universitari Vall d'Hebron)
Domingo-Santos, Ángela (Hospital Universitari Vall d'Hebron)
Guijarro-Castro, Cristina (Hospital Universitari Vall d'Hebron)
Íñiguez-Martínez, Cristina (Hospital Universitari Vall d'Hebron)
Téllez Lara, Nieves (Hospital Universitari Vall d'Hebron)
Castellanos-Pinedo, Fernando (Hospital Universitari Vall d'Hebron)
Castillo-Triviño, Tamara (Hospital Universitari Vall d'Hebron)
Cerdán-Santacruz, Debora María (Hospital Universitari Vall d'Hebron)
Torres, Berta Sebastián (Hospital Universitari Vall d'Hebron)
Álvarez de Arcaya, Amaya (Hospital Universitari Vall d'Hebron)
Costa-Arpín, Eva (Hospital Universitari Vall d'Hebron)
Durán-Ferreras, Eduardo (Hospital Universitari Vall d'Hebron)
González-Platas, Montserrat (Hospital Universitari Vall d'Hebron)
Landete Pascual, Lamberto (Hospital Universitari Vall d'Hebron)
Millán-Pascual, Jorge (Hospital Universitari Vall d'Hebron)
Oreja-Guevara, Celia (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Universitat Autònoma de Barcelona

Data:	2021
Resum:	To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state resulting from the use of disease-modifying treatments. Retrospective and multicenter registry in patients with MS with suspected or confirmed COVID-19 diagnosis and available disease course (mild = ambulatory; severe = hospitalization; and critical = intensive care unit/death). Cases were analyzed for associations between MS characteristics and COVID-19 course and for identifying risk factors for a fatal outcome. Of the 326 patients analyzed, 120 were cases confirmed by real-time PCR, 34 by a serologic test, and 205 were suspected. Sixty-nine patients (21. 3%) developed severe infection, 10 (3%) critical, and 7 (2. 1%) died. Ambulatory patients were higher in relapsing MS forms, treated with injectables and oral first-line agents, whereas more severe cases were observed in patients on pulsed immunosuppressors and critical cases among patients with no therapy. Severe and critical infections were more likely to affect older males with comorbidities, with progressive MS forms, a longer disease course, and higher disability. Fifteen of 33 patients treated with rituximab were hospitalized. Four deceased patients have progressive MS, 5 were not receiving MS therapy, and 2 were treated (natalizumab and rituximab). Multivariate analysis showed age (OR 1. 09, 95% CI, 1. 04-1. 17) as the only independent risk factor for a fatal outcome. This study has not demonstrated the presumed critical role of MS therapy in the course of COVID-19 but evidenced that people with MS with advanced age and disease, in progressive course, and those who are more disabled have a higher probability of severe and even fatal disease.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Neurology® neuroimmunology & neuroinflammation, Vol. 8 (june 2021) , ISSN 2332-7812

DOI: 10.1212/NXI.0000000000001024
PMID: 34168057

12 p, 302.7 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats